ES2184768T3 - Composiciones proteina:fosfolipido estables y metodos. - Google Patents

Composiciones proteina:fosfolipido estables y metodos.

Info

Publication number
ES2184768T3
ES2184768T3 ES94929959T ES94929959T ES2184768T3 ES 2184768 T3 ES2184768 T3 ES 2184768T3 ES 94929959 T ES94929959 T ES 94929959T ES 94929959 T ES94929959 T ES 94929959T ES 2184768 T3 ES2184768 T3 ES 2184768T3
Authority
ES
Spain
Prior art keywords
protein
phospholipide
stable
methods
protein compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94929959T
Other languages
English (en)
Inventor
David Collins
Younsik Cha
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ES2184768T3 publication Critical patent/ES2184768T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

LA INVENCION SE REFIERE A COMPOSICIONES ESTABLES DE PROTEINAS Y METODOS RELACIONADOS DONDE UNA PROTEINA CAPAZ DE CAMBIAR EN EL ESTADO GLOBULAR FUNDIDO SE PONE EN CONTACTO CON UNA VESICULA DE LIPIDO CARGADA NEGATIVAMENTE, ESTABILIZANDO ASI LA PROTEINA CONTRA EL AGREGADO TERMICAMENTE INDUCIDO, DESNATURALIZACION Y PERDIDA DE ACTIVIDAD. LA PROTEINA: COMPLEJO FOSFOLIPIDO ESTABILIZA DIRECTAMENTE LA ESTRUCTURA SECUNDARIA Y TERCIARIA DE LA PROTEINA, Y LAS COMPOSICIONES SON UTILES EN FORMULACIONES A ALTA TEMPERATURA Y EN NUEVOS VEHICULOS DE APLICACION.
ES94929959T 1993-10-06 1994-09-29 Composiciones proteina:fosfolipido estables y metodos. Expired - Lifetime ES2184768T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13241393A 1993-10-06 1993-10-06

Publications (1)

Publication Number Publication Date
ES2184768T3 true ES2184768T3 (es) 2003-04-16

Family

ID=22453938

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94929959T Expired - Lifetime ES2184768T3 (es) 1993-10-06 1994-09-29 Composiciones proteina:fosfolipido estables y metodos.

Country Status (20)

Country Link
EP (1) EP0671905B1 (es)
JP (1) JP2852127B2 (es)
KR (1) KR100372006B1 (es)
CN (1) CN1206982C (es)
AT (1) ATE222752T1 (es)
AU (1) AU683698B2 (es)
CA (1) CA2150939C (es)
CZ (1) CZ290029B6 (es)
DE (1) DE69431236T2 (es)
DK (1) DK0671905T3 (es)
ES (1) ES2184768T3 (es)
FI (1) FI116271B (es)
HU (1) HUT72326A (es)
IL (1) IL111170A (es)
NO (1) NO314064B1 (es)
NZ (1) NZ274705A (es)
PT (1) PT671905E (es)
RU (1) RU2119791C1 (es)
WO (1) WO1995009611A2 (es)
ZA (1) ZA947782B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874075A (en) * 1993-10-06 1999-02-23 Amgen Inc. Stable protein: phospholipid compositions and methods
DE69825137T2 (de) * 1998-02-23 2005-07-21 Cilag Ag International Liposomale Erythropoietin-Dispersion
DE69942581D1 (de) * 1998-05-25 2010-08-26 Nippon Shinyaku Co Ltd Verfahren zur herstellung einer nucleinsäure enthaltenden kompositzusammenstellung
GB0118517D0 (en) * 2001-07-30 2001-09-19 Mitsubishi Tokyo Pharm Inc Compound
US7863238B2 (en) 2004-06-10 2011-01-04 Saint Louis University Proteins with an attached short peptide of acidic amino acids
US7972593B2 (en) 2004-06-10 2011-07-05 Saint Louis University Delivery of therapeutic agents to the bone
JP2006248978A (ja) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
CN101990425B (zh) 2008-04-08 2016-01-20 默克专利股份有限公司 包含环肽的组合物和使用方法
CN104507953B (zh) * 2012-05-31 2018-05-18 新加坡科技研究局 通过用正电性有机添加剂处理来降低蛋白质制剂中蛋白质-污染物复合物和聚集物水平的方法
CN106170302B (zh) * 2014-04-04 2020-11-06 国立大学法人大阪大学 含有使溶血磷脂受体活化的物质的药剂递送促进剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04502768A (ja) * 1989-01-26 1992-05-21 アボット　バイオテク，インコーポレイテッド 疎水性蛋白質水溶液の安定化及び持続的放出ビヒクル
DK0456842T3 (da) * 1989-12-13 1996-04-15 Otsuka Pharma Co Ltd Medicinske anvendelser af M-CSF
DE4208527A1 (de) * 1992-03-17 1993-09-23 Max Planck Gesellschaft Liposomen mit negativer ueberschussladung
JPH06247842A (ja) * 1993-02-23 1994-09-06 Green Cross Corp:The リポソーム組成物の製造方法

Also Published As

Publication number Publication date
DE69431236T2 (de) 2003-01-02
AU7923994A (en) 1995-05-01
HK1010341A1 (en) 1999-06-17
CA2150939A1 (en) 1995-04-13
CA2150939C (en) 2001-05-01
DE69431236D1 (de) 2002-10-02
CZ290029B6 (cs) 2002-05-15
IL111170A (en) 1999-11-30
DK0671905T3 (da) 2002-10-07
HUT72326A (en) 1996-04-29
AU683698B2 (en) 1997-11-20
WO1995009611A2 (en) 1995-04-13
ATE222752T1 (de) 2002-09-15
KR960700042A (ko) 1996-01-19
NO952210L (no) 1995-08-04
ZA947782B (en) 1995-05-17
FI952738A0 (fi) 1995-06-05
IL111170A0 (en) 1994-12-29
RU2119791C1 (ru) 1998-10-10
NO314064B1 (no) 2003-01-27
FI116271B (fi) 2005-10-31
JPH08505403A (ja) 1996-06-11
JP2852127B2 (ja) 1999-01-27
WO1995009611A3 (en) 1995-06-22
PT671905E (pt) 2002-12-31
CN1117266A (zh) 1996-02-21
FI952738L (fi) 1995-07-31
CN1206982C (zh) 2005-06-22
EP0671905B1 (en) 2002-08-28
NZ274705A (en) 1997-12-19
NO952210D0 (no) 1995-06-02
EP0671905A1 (en) 1995-09-20
CZ143895A3 (en) 1996-01-17
KR100372006B1 (ko) 2003-07-18
HU9502053D0 (en) 1995-10-30

Similar Documents

Publication Publication Date Title
ES2177781T3 (es) Composiciones estables de proteina-fosfolipido y metodo de preparacion
EA199700289A1 (ru) Композиции для ухода за кожей, содержащие ретиноиды и липосомы
ES2184768T3 (es) Composiciones proteina:fosfolipido estables y metodos.
ES2042693T5 (es) Formulaciones de proteinas plasmaticas y recombinantes en medios de baja potencia ionica.
ATE187891T1 (de) Ophtalmische zusammensetzungen enthaltend amidoamine
ES2163627T3 (es) Metodo de elaboracion de composiciones congeladas.
HN1999000075A (es) Agonistas y antagonistas il-2 selectivos
NO980335L (no) Stabil isoton lyofilisert proteinformulering
ATE239123T1 (de) Funktionelle faserprodukte
EA199901013A1 (ru) Гели пролонгированного действия
BR9509172A (pt) Proteina de via de complemento nativa sequéncia de dna construção de dna conjugado uso de uma proteína processo para reduzir proteina de via de complemento em um mamifero e formulação farmacéutica
ATE301986T1 (de) Kosmetische stiftzubereitung
ES2042437T1 (es) Procedimiento de preparacion de una lipoproteina modificaa por incorporacion de una substancia activa lipofila.
DE69325493D1 (de) Künstliche Speichelzusammensetzungen
DK0686694T3 (da) Anvendelse af azoler som virucide midler i opløsninger af biologisk aktive proteiner
ATE239499T1 (de) Protein-disulfid-isomerasen enthaltende pharmazeutische zusammensetzungen
ES2051183B1 (es) Composicion explosiva
ECSP972005A (es) Agentes anticoagulantes utiles en el tratamiento de trombosis
RU95108442A (ru) Пепельница-сувенир
KR970028126U (ko) 사출금형의 분할핀
ES2139292T3 (es) Metodo y estuche (kit) para purificar acidos nucleicos.